{"componentChunkName":"component---src-templates-topic-topic-tsx","path":"/topics/nsaids-prescribing-issues/","result":{"data":{"firstChapter":{"id":"81e21dc7-3fa3-5a27-a799-d7e553aa1b01","slug":"summary","fullItemName":"Summary","subChapters":[],"depth":1,"htmlHeader":"<!-- begin field 1d2ace4e-b745-4cd2-941c-74e86b406619 --><h1>NSAIDs - prescribing issues: Summary</h1><!-- end field 1d2ace4e-b745-4cd2-941c-74e86b406619 -->","htmlStringContent":"<!-- begin item 7a7a0351-b34b-4113-a327-079cc22e1ba9 --><!-- begin field 4771d651-ed1b-4261-8bba-07853de6792c --><ul><li>Nonsteroidal anti-inflammatory drugs (NSAIDs) have analgesic, antipyretic and, at higher doses, anti-inflammatory actions.</li><li>NSAIDs inhibit prostaglandin synthesis by reversibly inhibiting cyclo-oxygenase (COX) enzymes — the two main types of COX enzyme are COX-1 and COX-2, which have different physiological functions.<ul><li>COX-1 produces prostaglandins that help to maintain gastric mucosal integrity and platelet-initiated blood clotting. Inhibition is thought to be responsible for gastrointestinal toxicity.</li><li>COX-2 produces prostaglandins that mediate pain and inflammation. Inhibition is thought to be responsible for the anti-inflammatory action of NSAIDs.</li></ul></li><li>NSAIDs vary in how selective they are for COX-1 and COX-2 pathways and the degree of selectivity for COX-1 relative to COX-2 can be used to classify NSAIDs:<ul><li>Standard NSAIDs — these are nonselective NSAIDs (inhibiting both COX-1 and COX-2), and include ibuprofen, indometacin, mefenamic acid, and naproxen. Diclofenac, etodolac, meloxicam, and nabumetone, are also nonselective NSAIDs, but are thought to have a preference for COX-2.</li><li>Coxibs — these are COX-2 specific NSAIDs, and include celecoxib and etoricoxib. </li></ul></li><li>When prescribing an NSAID, individual risk factors for adverse effects should be taken into account and include any contraindications, drug interactions, medical history, and any monitoring requirements.</li><li>If an NSAID is indicated, the lowest effective dose should be used for the shortest possible duration.</li><li>For people with:<ul><li>Severe heart failure — NSAIDs should be avoided. </li><li>Mild, moderate, or severe heart failure — COX-2 inhibitors, diclofenac, and high-dose ibuprofen (2400 mg or more daily) should be avoided.</li><li>Mild to moderate heart failure — a standard NSAID should be prescribed (but not diclofenac or high-dose ibuprofen), and the person should be monitored closely.<ul><li>Ibuprofen up to 1200 mg daily, or naproxen up to 1000 mg daily, should be first-line options.</li></ul></li></ul></li><li>For people with ischaemic heart disease, cerebrovascular disease, or peripheral arterial disease, ibuprofen up to 1200 mg per day or naproxen up to 1000 mg daily, should be first-line options.<ul><li>COX-2 inhibitors, diclofenac, and high-dose ibuprofen are contraindicated.</li></ul></li><li>For people with severe renal impairment (estimated glomerular filtration rate [eGFR] less than 30 mL/minute/1.73 m<sup>2</sup>), ideally NSAIDs should be avoided. <ul><li>If an NSAID is used, the person should be monitored closely.</li></ul></li><li>For people with risk factors for cardiovascular disease and all elderly people, ibuprofen up to 1200 mg per day or naproxen up to 1000 mg daily should be prescribed.</li><li>For people with uncontrolled hypertension (blood pressure persistently above 140/90 mmHg), etoricoxib and high-dose ibuprofen should be avoided. </li><li>To prevent GI adverse effects associated with NSAIDs:<ul><li>An alternative analgesic should be considered.</li><li>Prescribing more than one NSAID at a time should be avoided.</li><li>Concomitant use of an NSAID with low-dose aspirin should be avoided </li><li>Short-acting NSAIDs (such as ibuprofen) should be used in preference to long-acting formulations (such as naproxen). </li></ul></li><li>For people at:<ul><li>High risk of GI adverse events — a COX-2 inhibitor should be prescribed with a proton pump inhibitor (PPI). </li><li>Moderate risk of GI adverse events — a COX-2 inhibitor should be prescribed alone, or an NSAID plus a PPI. </li><li>Low risk of GI events — a non-selective NSAID should be prescribed.</li></ul></li></ul><!-- end field 4771d651-ed1b-4261-8bba-07853de6792c --><!-- end item 7a7a0351-b34b-4113-a327-079cc22e1ba9 -->","topic":{"id":"ceac2e33-6fd9-5bdf-a103-bdeff3e6efe7","topicId":"5e29889f-d8f4-4f4e-9bce-78c262cd5e62","topicName":"NSAIDs - prescribing issues","slug":"nsaids-prescribing-issues","aliases":[],"chapters":[{"id":"81e21dc7-3fa3-5a27-a799-d7e553aa1b01","slug":"summary","fullItemName":"Summary","subChapters":[]},{"id":"e5927ea9-133a-5f9b-a357-a61c0992b6c6","slug":"have-i-got-the-right-topic","fullItemName":"Have I got the right topic?","subChapters":[]},{"id":"f8ed8fe1-df7d-5125-937f-2d1e3501233c","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?","subChapters":[{"id":"f6920c2a-03f6-5506-aec1-3fdde89dd2f7","slug":"changes","fullItemName":"Changes"},{"id":"7e3ebe71-e455-5372-ae22-416ce6a0b71a","slug":"update","fullItemName":"Update"}]},{"id":"acb8e014-609e-5dc6-9f65-30c1458821c4","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures","subChapters":[{"id":"93d7bec8-79d3-5e43-b717-afe25c73d3ca","slug":"goals","fullItemName":"Goals"},{"id":"80a6271f-7ea5-5a98-902b-a008dc09f1ee","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"6782e03f-1ef7-5af4-86c0-eb675a202116","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"fcacc99e-0dfb-5679-b56f-f8205eba1edc","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"15a07f25-5af2-57a1-a7ac-048177f2fb99","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"39c204ac-0dfe-5334-ba6a-72f81053bd3d","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"9ce106c0-0dc6-5564-9353-be22c8fc1ed5","slug":"background-information","fullItemName":"Background information","subChapters":[{"id":"0cc396a7-37bb-55ac-a9b6-83b76805f342","slug":"definition","fullItemName":"Definition"},{"id":"d742f98e-351a-50ba-bc7a-d0ecc0e7689d","slug":"mode-of-action","fullItemName":"Mode of action"},{"id":"93f69297-618f-59f0-b4d4-f6e50bdf5467","slug":"classification","fullItemName":"Classification"}]},{"id":"6537c6fb-b310-5291-98df-d01a4e961e7e","slug":"management","fullItemName":"Management","subChapters":[{"id":"f7cf8186-98aa-5332-bbd7-7ac7f7c5748e","slug":"nsaids-prescribing-issues","fullItemName":"Scenario: NSAIDs  prescribing issues"}]},{"id":"1e3b7407-6a49-5511-bff4-c0f0e8e7b22e","slug":"supporting-evidence","fullItemName":"Supporting evidence","subChapters":[]},{"id":"56eccf0e-4660-56df-8972-3fc937ad78b7","slug":"how-this-topic-was-developed","fullItemName":"How this topic was developed","subChapters":[{"id":"80126798-6f53-5ceb-b2d7-d2c5adf206da","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"0e838f63-dbcc-5df4-ba98-67f8c94448ed","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"179593fd-6f34-5834-a706-a5b7abb725a3","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"b21e3781-fcad-52bd-b0b3-0b7f267e817d","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"ece91260-71c4-51d6-bc77-400de18b4802","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"dedb4c68-d2e7-53bb-81ef-03a9600c383d","slug":"references","fullItemName":"References","subChapters":[]}]}},"topic":{"id":"ceac2e33-6fd9-5bdf-a103-bdeff3e6efe7","topicId":"5e29889f-d8f4-4f4e-9bce-78c262cd5e62","topicName":"NSAIDs - prescribing issues","slug":"nsaids-prescribing-issues","aliases":[],"topicSummary":"Nonsteroidal anti-inflammatory drugs (NSAIDs) inhibit cyclo-oxygenase (COX) enzymes","lastRevised":"Last revised in April 2020","nextPlannedReviewBy":"2023-08-01T00:00:00+01:00","nextPlannedReviewByDateTime":"2023-07","nextPlannedReviewByDisplay":"July 2023","specialities":[{"id":"45db1917-4d65-58d8-af3d-568321e486ed","name":"Drugs and devices","slug":"drugs-devices"},{"id":"e4fd15e3-ef70-523f-843c-5270742f518d","name":"Gastrointestinal","slug":"gastrointestinal"},{"id":"f8332083-731e-50fe-a895-030315ce6083","name":"Musculoskeletal","slug":"musculoskeletal"}],"chapters":[{"id":"81e21dc7-3fa3-5a27-a799-d7e553aa1b01","slug":"summary","fullItemName":"Summary","subChapters":[]},{"id":"e5927ea9-133a-5f9b-a357-a61c0992b6c6","slug":"have-i-got-the-right-topic","fullItemName":"Have I got the right topic?","subChapters":[]},{"id":"f8ed8fe1-df7d-5125-937f-2d1e3501233c","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?","subChapters":[{"id":"f6920c2a-03f6-5506-aec1-3fdde89dd2f7","slug":"changes","fullItemName":"Changes"},{"id":"7e3ebe71-e455-5372-ae22-416ce6a0b71a","slug":"update","fullItemName":"Update"}]},{"id":"acb8e014-609e-5dc6-9f65-30c1458821c4","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures","subChapters":[{"id":"93d7bec8-79d3-5e43-b717-afe25c73d3ca","slug":"goals","fullItemName":"Goals"},{"id":"80a6271f-7ea5-5a98-902b-a008dc09f1ee","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"6782e03f-1ef7-5af4-86c0-eb675a202116","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"fcacc99e-0dfb-5679-b56f-f8205eba1edc","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"15a07f25-5af2-57a1-a7ac-048177f2fb99","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"39c204ac-0dfe-5334-ba6a-72f81053bd3d","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"9ce106c0-0dc6-5564-9353-be22c8fc1ed5","slug":"background-information","fullItemName":"Background information","subChapters":[{"id":"0cc396a7-37bb-55ac-a9b6-83b76805f342","slug":"definition","fullItemName":"Definition"},{"id":"d742f98e-351a-50ba-bc7a-d0ecc0e7689d","slug":"mode-of-action","fullItemName":"Mode of action"},{"id":"93f69297-618f-59f0-b4d4-f6e50bdf5467","slug":"classification","fullItemName":"Classification"}]},{"id":"6537c6fb-b310-5291-98df-d01a4e961e7e","slug":"management","fullItemName":"Management","subChapters":[{"id":"f7cf8186-98aa-5332-bbd7-7ac7f7c5748e","slug":"nsaids-prescribing-issues","fullItemName":"Scenario: NSAIDs  prescribing issues"}]},{"id":"1e3b7407-6a49-5511-bff4-c0f0e8e7b22e","slug":"supporting-evidence","fullItemName":"Supporting evidence","subChapters":[]},{"id":"56eccf0e-4660-56df-8972-3fc937ad78b7","slug":"how-this-topic-was-developed","fullItemName":"How this topic was developed","subChapters":[{"id":"80126798-6f53-5ceb-b2d7-d2c5adf206da","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"0e838f63-dbcc-5df4-ba98-67f8c94448ed","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"179593fd-6f34-5834-a706-a5b7abb725a3","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"b21e3781-fcad-52bd-b0b3-0b7f267e817d","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"ece91260-71c4-51d6-bc77-400de18b4802","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"dedb4c68-d2e7-53bb-81ef-03a9600c383d","slug":"references","fullItemName":"References","subChapters":[]}]}},"pageContext":{"id":"ceac2e33-6fd9-5bdf-a103-bdeff3e6efe7"}},"staticQueryHashes":["3666801979"]}